Dose-dependent enhancement of spinal fusion in rats with teriparatide (PTH[1-34]).

Ming N, Cheng JT, Rui YF, Chan KM, Kuhstoss S, Ma YL, Sato M, Wang Y, Li G

Spine1 Jul 2012Cited by 35 (Europe PMC)

PMID22281479DOI10.1097/brs.0b013e31824ac089PepBankPUB-22281479

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, the radiographic fusion score was numerically higher with low-dose teriparatide than vehicle.
In plain wordsIn rats, low-dose teriparatide had a numerically higher radiographic fusion score than vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadiographic fusion score at low dose
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
4 μg/kg/day · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Measurements
Fusion score
2.87 score
PTH4
Fusion score
1.53 score
vehicle
Source sentences
Summary
The average radiographical score of L5-L6 fusion in Vehicle, PTH4, and PTH23 groups was 1.53, 2.87, and 4.11, respectively, with the PTH23 being significantly higher (P = 0.001 vs. Vehicle).
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147901
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, high-dose teriparatide significantly increased radiographic fusion score versus vehicle.
In plain wordsIn rats, high-dose teriparatide increased radiographic fusion score compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadiographic fusion score at high dose
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
23 μg/kg/day · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Measurements
Fusion score
4.11 score
PTH23
Fusion score
1.53 score
vehicle
Source sentences
Summary
The average radiographical score of L5-L6 fusion in Vehicle, PTH4, and PTH23 groups was 1.53, 2.87, and 4.11, respectively, with the PTH23 being significantly higher (P = 0.001 vs. Vehicle).
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147902
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, low-dose teriparatide had a numerically higher microCT fusion score than vehicle.
In plain wordsIn rats, low-dose teriparatide had a numerically higher scan-based fusion score than vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMicroCT fusion score at low dose
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
4 μg/kg/day · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Measurements
Fusion score
2.4 score
PTH4
Fusion score
1.53 score
vehicle
Source sentences
Summary
The average micro-computed tomographic score of L5-L6 fusion in Vehicle, PTH4, and PTH23 groups was 1.53, 2.40, and 3.74, respectively (P = 0.001, PTH23 vs. Vehicle and PTH4).
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147903
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, high-dose teriparatide significantly increased microCT fusion score versus vehicle.
In plain wordsIn rats, high-dose teriparatide increased scan-based fusion score compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMicroCT fusion score at high dose versus vehicle
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
23 μg/kg/day · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Measurements
Fusion score
3.74 score
PTH23
Fusion score
1.53 score
vehicle
Source sentences
Summary
The average micro-computed tomographic score of L5-L6 fusion in Vehicle, PTH4, and PTH23 groups was 1.53, 2.40, and 3.74, respectively (P = 0.001, PTH23 vs. Vehicle and PTH4).
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147904
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, high-dose teriparatide significantly increased microCT fusion score versus low-dose teriparatide.
In plain wordsIn rats, high-dose teriparatide increased scan-based fusion score compared with low-dose teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMicroCT fusion score at high versus low dose
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Teriparatide 4 μg/kg/day
Outcome group
Bone and joint · Musculoskeletal
Studied dose
23 μg/kg per day · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
The average micro-computed tomographic score of L5-L6 fusion in Vehicle, PTH4, and PTH23 groups was 1.53, 2.40, and 3.74, respectively (P = 0.001, PTH23 vs. Vehicle and PTH4).
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147905
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, manual fusion rates were numerically higher with low-dose teriparatide than vehicle.
In plain wordsIn rats, low-dose teriparatide had a numerically higher manual fusion rate than vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseManual fusion rate at low dose
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
4 μg/kg/day · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Measurements
Fusion rate
50%
PTH4
Fusion rate
20%
vehicle
Source sentences
Summary
Manual palpation showed that fusion rate was 20%, 50%, and 67.7% in Vehicle, PTH4, and PTH23 groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147906
07AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, manual fusion rates were numerically higher with high-dose teriparatide than vehicle.
In plain wordsIn rats, high-dose teriparatide had a numerically higher manual fusion rate than vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseManual fusion rate at high dose
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
23 μg/kg/day · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Measurements
Fusion rate
67.7%
PTH23
Fusion rate
20%
vehicle
Source sentences
Summary
Manual palpation showed that fusion rate was 20%, 50%, and 67.7% in Vehicle, PTH4, and PTH23 groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147907
08AnimalAnimal study (in vivo)Efficacy outcome
In rats with spinal grafts, teriparatide increased mineral apposition rate in a dose-dependent manner across treatment groups.
In plain wordsIn rats, bone mineral deposition increased with teriparatide dose compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMineral apposition rate at fusion site
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
The bone mineralization apposition rate at the fusion site was significantly increased in a dose-dependent manner among the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147908
09AnimalAnimal study (in vivo)Efficacy outcome
In rats, teriparatide increased vertebral BMD in a dose-dependent manner versus vehicle.
In plain wordsIn rats, teriparatide increased vertebral bone density with dose compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral BMD
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
Teriparatide significantly increased vertebral and femoral bone mineral density, bone mineral content, and trabecular area in a dose-dependent manner relative to Vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147909
10AnimalAnimal study (in vivo)Efficacy outcome
In rats, teriparatide increased femoral BMD in a dose-dependent manner versus vehicle.
In plain wordsIn rats, teriparatide increased thighbone density with dose compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral BMD
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
Teriparatide significantly increased vertebral and femoral bone mineral density, bone mineral content, and trabecular area in a dose-dependent manner relative to Vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147910
11AnimalAnimal study (in vivo)Efficacy outcome
In rats, teriparatide increased vertebral bone mineral content in a dose-dependent manner versus vehicle.
In plain wordsIn rats, teriparatide increased vertebral bone mineral content with dose compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral bone mineral content
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
Teriparatide significantly increased vertebral and femoral bone mineral density, bone mineral content, and trabecular area in a dose-dependent manner relative to Vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147911
12AnimalAnimal study (in vivo)Efficacy outcome
In rats, teriparatide increased femoral bone mineral content in a dose-dependent manner versus vehicle.
In plain wordsIn rats, teriparatide increased thighbone mineral content with dose compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral bone mineral content
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
Teriparatide significantly increased vertebral and femoral bone mineral density, bone mineral content, and trabecular area in a dose-dependent manner relative to Vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147912
13AnimalAnimal study (in vivo)Efficacy outcome
In rats, teriparatide increased vertebral trabecular area in a dose-dependent manner versus vehicle.
In plain wordsIn rats, teriparatide increased vertebral trabecular area with dose compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral trabecular area
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
Teriparatide significantly increased vertebral and femoral bone mineral density, bone mineral content, and trabecular area in a dose-dependent manner relative to Vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147913
14AnimalAnimal study (in vivo)Efficacy outcome
In rats, teriparatide increased femoral trabecular area in a dose-dependent manner versus vehicle.
In plain wordsIn rats, teriparatide increased thighbone trabecular area with dose compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral trabecular area
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
Teriparatide significantly increased vertebral and femoral bone mineral density, bone mineral content, and trabecular area in a dose-dependent manner relative to Vehicle.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147914
15AnimalAnimal study (in vivo)Efficacy outcome
In rats, serum procollagen type I N-terminal propeptide did not differ between treatment groups at 4 weeks.
In plain wordsIn rats, this bone formation marker did not differ between teriparatide and control treatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum procollagen type I N-terminal propeptide
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
No difference was found between the circulating Procollagen type I N-terminal propeptide and intact osteocalcin levels in the serum at 4 weeks after treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147915
16AnimalAnimal study (in vivo)Efficacy outcome
In rats, serum intact osteocalcin did not differ between treatment groups at 4 weeks.
In plain wordsIn rats, intact osteocalcin did not differ between teriparatide and control treatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum intact osteocalcin
Study
ratn: not reported in source
L5-L6 spinal fusion model
Comparator
Saline vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 4 weeks, 5 days per weekAs given in this study (rat).
Source sentences
Summary
No difference was found between the circulating Procollagen type I N-terminal propeptide and intact osteocalcin levels in the serum at 4 weeks after treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
Rats were randomly assigned into 3 groups: saline vehicle control (Vehicle), teriparatide 4 μg/kg per day (PTH4), and teriparatide 23 μg/kg per day (PTH23) subcutaneous injections for 4 weeks (5 d per wk).
Report a problemFND-2228147916

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.